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Neocortex expansion during mammalian evolution
has been linked to an increase in proliferation of
basal progenitors in the subventricular zone. Here,
we explored a potential role of YAP, the major down-
stream effector of the Hippo pathway, in proliferation
of basal progenitors. YAP expression and activity are
high in ferret and human basal progenitors, which
exhibit high proliferative capacity, but low in mouse
basal progenitors, which lack such capacity. Condi-
tional expression of a constitutively active YAP in
mouse basal progenitors resulted in increased prolif-
eration of basal progenitor and promoted production
of upper-layer neurons. Pharmacological and ge-
netic interference with YAP function in ferret and
human developing neocortex resulted in decreased
abundance of cycling basal progenitors. Together,
our data indicate that YAP is necessary and sufficient
to promote the proliferation of basal progenitors and
suggest that increases in YAP levels and presumably
activity contributed to the evolutionary expansion of
the neocortex.
INTRODUCTION
The neocortex, the seat of higher cognitive functions, undergoes
substantial expansion during the evolution of certain mammalian
brains such as human. A major factor in neocortical expansion,
notably regarding the increase in the number of cortical neurons,
is thought to be an increased proliferative capacity of cortical
neural progenitor cells (cNPCs) (Fietz and Huttner, 2011; Florio
and Huttner, 2014; Geschwind and Rakic, 2013; Lui et al.,Cell
This is an open access article und2011; Namba and Huttner, 2017; Rakic, 2009; Wilsch-Bra¨u-
ninger et al., 2016).
Two principal classes of cNPCs exist in the developing
neocortex, referred to as apical progenitors (APs) and basal pro-
genitors (BPs) (Florio and Huttner, 2014; Lui et al., 2011; Namba
and Huttner, 2017). The defining feature of APs is that they
undergo mitosis at the ventricular (apical) surface of the ventric-
ular zone (VZ), the primary germinal zone where the AP cell
bodies reside (Florio and Huttner, 2014; Namba and Huttner,
2017). At the onset of neurogenesis, apical (or ventricular) radial
glia (aRG) are the major AP cell type (Fietz and Huttner, 2011;
Florio and Huttner, 2014; Lui et al., 2011; Namba and Huttner,
2017). The defining feature of BPs is that they undergo mitosis
away from the apical surface, typically in a secondary germinal
zone called the subventricular zone (SVZ) where the BP cell
bodies reside (Haubensak et al., 2004; Miyata et al., 2004; Noc-
tor et al., 2004). BPs originate from APs, delaminate from the
apical surface, migrate beyond the VZ, and thus form the SVZ.
There are twomain types of BPs, basal intermediate progenitors
(bIPs) and basal (or outer) radial glia (bRG). In contrast to aRG,
which are epithelial cells exhibiting apical-basal polarity with
contact to the ventricle and (in the canonical form) to the basal
lamina, bIPs are non-epithelial cells that no longer exhibit api-
cal-basal polarity and have lost contact with both the ventricle
and the basal lamina (Haubensak et al., 2004; Miyata et al.,
2004; Noctor et al., 2004). bRG, however, though lacking an api-
cal process that reaches the ventricle, retain epithelial features
in that they (in the canonical form) possess a basal process that
contacts the basal lamina (Betizeau et al., 2013; Fietz et al.,
2010; Hansen et al., 2010; Reillo et al., 2011).
BP composition and proliferative capacity may differ greatly
between a developing lissencephalic neocortex (e.g., mouse)
and a developing gyrencephalic neocortex (e.g., ferret and
human). In the developing mouse neocortex, BPs mostly
comprise bIPs that typically undergo neurogenic consumptiveReports 27, 1103–1118, April 23, 2019 ª 2019 The Author(s). 1103
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
divisions giving rise to two neurons; compared to the aRG they
derive from, these neurogenic bIPs characteristically upregulate
the transcription factor Tbr2 and downregulate the transcription
factor Sox2 (Haubensak et al., 2004; Miyata et al., 2004; Noctor
et al., 2004). Only a minor portion of mouse BPs are bRG, and
their proliferative potential is limited (Shitamukai et al., 2011;
Wang et al., 2011). In contrast, in the developing ferret and hu-
man neocortex, the majority of BPs are proliferative bRG (highly
proliferative in human) that do not express Tbr2 but rather main-
tain expression of Sox2 (Fietz et al., 2010; Hansen et al., 2010;
Reillo et al., 2011). Moreover, as first shown in a seminal contri-
bution for the developing monkey neocortex (Smart et al., 2002),
the SVZ in a gyrencephalic neocortex is characteristically split
into two morphologically distinct zones, an inner SVZ (iSVZ)
and an outer SVZ (oSVZ). Of note, the evolutionary expansion
of the neocortex has been linked to an increase in the prolifera-
tive capacity and abundance of BPs in the oSVZ, especially of
bRG (Dehay et al., 2015; Fietz and Huttner, 2011; Lui et al.,
2011; Namba and Huttner, 2017). However, the molecular
players that differentially promote the proliferative capacity of
BPs across the various mammalian species remain largely
unknown.
To gain insight into this issue, we examined a major molec-
ular mechanism known to regulate organ size, the Hippo-YAP
signaling pathway (Barry and Camargo, 2013; Camargo et al.,
2007; Lian et al., 2010; Yu et al., 2015). The core of Hippo-YAP
signaling is the YAP protein, whose ability to activate tran-
scription is regulated by phosphorylation. Phosphorylated
YAP (phospho-YAP) is largely retained in the cytoplasm,
whereas dephosphorylated YAP (dephospho-YAP) can trans-
locate to the nucleus and activate the expression of genes
linked to cell proliferation (Zanconato et al., 2015; Zhao
et al., 2007, 2008, 2010). Recent studies dissecting the roles
of the cadherin family members Dchs1 and Fat4 (Cappello
et al., 2013) and the tumor suppressor neurofibromatosis 2
(Lavado et al., 2013, 2014) and investigating heterotopia for-
mation (Saito et al., 2018) in mouse brain development have
reported that YAP promotes the proliferation of mouse APs.
These studies, however, have not focused on a potential role
of YAP in regulating the proliferation of BPs, nor have they ad-
dressed whether differences in YAP activity may underlie the
differences in the proliferative capacity of BPs across various
mammalian species in the context of the evolutionary expan-
sion of the neocortex.
In the present study, we have identified differences in YAP
expression and YAP activity between the developing lissence-
phalic mouse and gyrencephalic ferret and human neocortex
that match the differences in the proliferative capacity of BPs
across these species. Enhancing YAP activity in mouse BPs
induced their proliferation and therefore shifted their fate from
neurogenic to proliferative. In contrast, inhibition of endogenous
YAP activity by verteporfin, administration of a dominant-nega-
tive YAP, or CRISPR-Cas9-mediated disruption of YAP expres-
sion reduced BP proliferation in developing ferret and human
neocortex. Taken together, these findings suggest that an upre-
gulation of YAP levels and presumably activity contributed to the
increased proliferative capacity of BPs in the context of the
evolutionary expansion of the neocortex.1104 Cell Reports 27, 1103–1118, April 23, 2019RESULTS
BPs with High Proliferative Capacity, which Are
Abundant in Embryonic Ferret and Fetal Human
Neocortex but Lacking in Embryonic Mouse Neocortex,
Show High YAP Expression
We first exploited previously published transcriptome datasets
(Fietz et al., 2012; Florio et al., 2015) to analyze the levels of
Yap-YAP mRNA in the germinal zones and cNPC classes of
developing mouse and human neocortex (Figure S1). Yap-YAP
mRNA was robustly expressed in the VZ of both embryonic
day 14.5 (E14.5) mouse and 13 weeks post-conception
(13 wpc) human neocortex (Figure S1A) and accordingly in
mouse and human aRG (Figure S1B). Moreover, Yap expression
was 2-fold higher in Tis21-GFP-negative (i.e., proliferative) aRG
than Tis21-GFP-positive (i.e., BP-genic) aRG of E14.5 mouse
neocortex (Figure S1C; see below for the specificity of Tis21
gene expression) (Florio et al., 2015). Strikingly, Yap-YAP
mRNA was found to be expressed in the human iSVZ and
oSVZ, but not the mouse SVZ (Figure S1A), and in human
bRG, but not mouse BPs (Figure S1B). Given that both human
and mouse proliferative APs and human, but not mouse, BPs
are endowed with the ability to expand their population size by
cell proliferation (Namba andHuttner, 2017), these data provided
a first indication that the proliferative capacity of cNPCs, notably
of BPs, may be linked to the expression of YAP. Consistent with
this notion, no significant Yap-YAP mRNA expression was de-
tected in the mouse and human cortical plate (CP) (Figure S1A)
or in post-mitotic neurons (Figure S1B).
Comparison of mRNA levels between a prospective gyrus
versus a prospective sulcus of developing (postnatal day 2
[P2]) ferret neocortex, available in a previously published tran-
scriptome dataset (de Juan Romero et al., 2015), showed that
the Yap mRNA level was higher in the oSVZ of the prospective
gyrus than the prospective sulcus (Figure S1D), consistent with
the notion that a relative increase in cNPC proliferation in this
germinal zone contributes to gyrus formation (Hansen et al.,
2010; Reillo et al., 2011; Wang et al., 2011). Taken together,
these Yap-YAP mRNA data raised the possibility not only that
YAP may have a role in the proliferation of APs, as previously
shown for embryonic mouse neocortex (Lavado et al., 2013,
2014), but also that differences in the level of active YAP may
underlie the differences in the proliferative capacity of mouse
versus ferret and human BPs.
We therefore examined the expression of the YAP protein in
embryonic mouse, embryonic ferret, and fetal human neocortex
by immunofluorescence (Figures 1A–1C and 1F–1H). Consistent
with the mRNA expression data (Figure S1A), YAP immunoreac-
tivity was overt in the E14.5mouse, E36 ferret, and 14wpchuman
VZ and in the ferret and human SVZ, notably the oSVZ, but was
low in the mouse SVZ (Figures 1A–1C). In the case of the embry-
onic ferret oSVZ, YAP immunostaining revealed cells exhibiting a
basal process (Figure 1B0), suggesting that they were bRG.
YAP-Expressing BPs in Embryonic Ferret and Fetal
Human Neocortex Are Sox2 Positive
For YAP to be able to promote the expression of genes linked to
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et al., 2007, 2008, 2010). Interestingly, in line with a potential role
of YAP in BP proliferation, the 13–14 wpc human SVZ contained
the highest percentage of YAP-positive nuclei (50%), followed
by the E36 ferret SVZ (15%), whereas the E14.5 mouse SVZ
exhibited low levels of YAP-positive nuclei (4%) (Figure 1D).
We sought to obtain direct evidence that the higher level of
nuclear YAP protein seen in embryonic ferret and fetal human
SVZ as compared to mouse SVZ (Figure 1D) is linked to the
increased proliferative capacity of ferret and human BPs versus
mouse BPs. To this end, we compared the expression of YAP
with that of Sox2 (Figures 1A–1C), an indicator of proliferative
capacity (Hansen et al., 2010; Reillo et al., 2011; Wang et al.,
2011). Specifically, we asked whether SVZ nuclei positive for
Sox2 are also positive for YAP. Indeed, the vast majority of the
Sox2-positive BP nuclei in the E36 ferret and 13–14 wpc human
SVZ were YAP positive (70% and 86%, respectively), whereas
this was the case for only aminor proportion of the Sox2-positive
nuclei in the E14.5 mouse SVZ (4%) (Figure 1E).
YAP in Sox2-Positive BP Nuclei in Embryonic Ferret and
Fetal HumanNeocortex, in Contrast to that in Embryonic
Mouse Neocortex, Is Mostly Dephosphorylated
Phosphorylation of YAP at specific serine residues (serine 127 in
the case of human YAP) leads to its interaction with 14-3-3 pro-
teins, which in turn results in the retention of YAP in the cyto-
plasm, rendering it unable to activate transcription (Moya and
Halder, 2019). However, phospho-YAP is not necessarily
completely retained in the cytoplasm but can also in part be
localized in the nucleus (Das et al., 2016). Within the nucleus,
YAP phosphorylated at serine 127 tends to interact more with
p73, resulting in activation of genes involved in apoptosis, rather
than with TEA domain transcription factor (TEAD), which would
result in activation of genes involved in cell proliferation (Down-
ward and Basu, 2008; Matallanas et al., 2007). We therefore
investigated whether the YAP protein in Sox2-positive BP nuclei
was in a dephosphorylated state. At first, qualitative indication
that this was the case was obtained by comparing the immuno-
fluorescence signals for total YAP and phospho-YAP in Sox2-
positive BP nuclei in the SVZ of human 11 wpc neocortex (Fig-
ure S2A). Relative to the cytoplasmic signals for total YAP and
phospho-YAP, respectively, this comparison showed a muchFigure 1. The Majority of Ferret and Human, but Not Mouse, Sox2-Pos
(A–C) Double immunofluorescence for YAP (green) and Sox2 (magenta), combin
14 wpc (C) neocortex. Boxes indicate areas in the SVZ (A) and oSVZ (B andC) that
that are YAP negative in mouse and YAP positive in ferret and human are outline
(D and E) Quantification of the percentage of DAPI-stained nuclei (D) and Sox2-po
human 13–14 wpc neocortex. Two or three images per embryo-fetus were taken,
SVZ were scored per image, and the values obtained were averaged for each em
(F–H) Double immunofluorescence for YAP (green) and Tbr2 (magenta), combin
11 wpc (H) neocortex. Boxes indicate areas in the VZ and SVZ (F) or iSVZ (G and H
selected Tbr2-positive nuclei that are YAP negative in mouse, ferret, and human
(I–K) Quantification of the percentage of Tbr2-negative nuclei in the VZ (I), Tbr2-p
positive in mouse E14.5, ferret E36, and human 11wpc neocortex. Two or three im
the VZ (I) and Tbr2-positive nuclei in the VZ (J) and SVZ (K) were scored per imag
mean of three or four embryos-fetuses.
(A–C and F–H) Images are 1-mm optical sections. Scale bars represent 50 mm (A
(D, E, and I–K) Error bars indicate SEM; **p < 0.01, ***p < 0.001 (one-way ANOV
See also Figures S1 and S2.
1106 Cell Reports 27, 1103–1118, April 23, 2019lower signal for nuclear phospho-YAP than nuclear total YAP,
suggesting that most nuclear YAP in fetal human neocortical
BPs was in the dephosphorylated state. We therefore used this
approach to compare the relative levels of dephospho-YAP in
Sox2-positive BP nuclei in the SVZ of mouse E13.5, ferret E36,
and human 11 wpc neocortex. To this end, we subtracted the in-
ternal standard-adjusted immunofluorescence signal for nuclear
phospho-YAP from that of nuclear total YAP to obtain informa-
tion about the relative levels of nuclear dephospho-YAP (see Fig-
ure S2B legend for details). This revealed substantially higher
relative levels of dephospho-YAP in the Sox2-positive BP nuclei
of ferret E36 and human 11 wpc neocortex than mouse E13.5
neocortex (Figure S2B).
We complemented these data by determining the effect of
protein phosphatase treatment of cryosections on the YAP
immunofluorescence signals in Sox2-positive BP nuclei in
the SVZ of mouse E14.5, ferret E36, and human 12–13 wpc
neocortex. For YAP immunofluorescence, two rabbit mono-
clonal antibodies were used together, one recognizing YAP
irrespective of serine 127 (human) or serine 112 (mouse) phos-
phorylation (total YAP) and the other recognizing the serine 127
or serine 112 phosphorylation site when phosphorylated (phos-
pho-YAP). Hence, in the control (i.e., without protein phospha-
tase treatment), the YAP immunofluorescence signal reflects
the binding of primary antibodies to one or two sites, depending
on whether serine 127 or serine 112 is phosphorylated or not. In
the case of mouse, protein phosphatase treatment reduced the
YAP immunofluorescence signal by 40% compared to control
(Figure S2C). As protein phosphatase treatment of mouse E14.5
neocortex resulted in complete dephosphorylation of serine 112
(see STAR Methods), this 40% reduction suggested that
approximately two-thirds (40/60) of the YAP protein in Sox2-pos-
itive BP nuclei of mouse E14.5 neocortex was in phosphorylated
form. In contrast, in the case of ferret and human, protein phos-
phatase treatment reduced the YAP immunofluorescence signal
by only 20% and 10%, respectively, compared to the controls
(Figure S2C), consistent with only 25% (20/80) and 10%
(10/90) of the YAP protein in the Sox2-positive BP nuclei of ferret
E36 neocortex and human 12–13 wpc neocortex, respectively,
being in phosphorylated form. These data therefore corrobo-
rated our finding that there are markedly higher relative levelsitive Tbr2-Negative BPs Exhibit Nuclear YAP
ed with DAPI staining (white), of mouse E14.5 (A), ferret E36 (B), and human
are shown at highermagnification (A0, B0, and C0); selected Sox2-positive nuclei
d by white lines; arrowheads indicate a YAP-positive basal process of a bRG.
sitive nuclei (E) in the SVZ that are YAP positive in mouse E14.5, ferret E36, and
30 randomly picked DAPI-stained nuclei (D) and Sox2-positive nuclei (E) in the
bryo-fetus. Data are the mean of four embryos-fetuses.
ed with DAPI staining (white), of mouse E14.5 (F), ferret E36 (G), and human
) that are shown at higher magnification (F0, F00, G0, G00, H0, and H00), as indicated;
are outlined by white lines.
ositive nuclei in the VZ (J), and Tbr2-positive nuclei in the SVZ (K) that are YAP
ages per embryo-fetus were taken, 30 randomly picked Tbr2-negative nuclei in
e, and the values obtained were averaged for each embryo-fetus. Data are the
–C and F–H), 10 mm (A0, B0, and C0), and 20 mm (F0, F00, G0, G00, H0, and H00).
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of dephospho-YAP in the Sox2-positive BP nuclei of embryonic
ferret and fetal human than embryonic mouse neocortex.
Most Tbr2-Positive BPs in Embryonic Ferret and Fetal
Human Neocortex Lack YAP Expression
Results essentially opposite to the occurrence of YAP in Sox2-
positive BP nuclei were obtained when we compared the
expression of YAP with that of Tbr2 (Figures 1F–1H), which in
embryonic mouse neocortex has been established as a marker
of differentiating BPs, notably of neurogenic bIPs (Englund
et al., 2005; Kowalczyk et al., 2009; Pontious et al., 2008).
Thus, only a minor proportion (<16%) of the Tbr2-positive nuclei
in the E14.5mouse, E36 ferret, and 11wpc humanSVZwere also
positive for YAP (Figure 1K). Similarly, only 20% of the Tbr2-
positive nuclei in the VZ of developing mouse, ferret, and human
neocortex, which constitute newborn BPs (Arai et al., 2011),
were YAP positive (Figure 1J). In contrast, the overwhelming
majority (>75%) of the Tbr2-negative nuclei in the VZ of devel-
oping mouse, ferret, and human neocortex, which constitute
APs capable of expansion by proliferation, were YAP positive
(Figure 1I).
Taken together, these data suggest that the proliferative ca-
pacity of cNPCs, notably of BPs, correlates with the occurrence
of nuclear dephospho-YAP, with a high percentage of prolifer-
ating APs in developing mouse, ferret, and human neocortex
and proliferating BPs in embryonic ferret and fetal human
neocortex exhibiting nuclear (and mostly active) YAP, whereas
this was the case for only a low percentage of the proliferating
BPs in embryonic mouse neocortex. Conversely, only a low per-
centage of the nuclei of differentiating (rather than proliferating)
BPs in the developing mouse, ferret, and human neocortex ex-
hibited nuclear YAP (and hence nuclear YAP activity, if any).
Conditional Expression of Constitutively Active YAP in
Embryonic Mouse Neocortex Decreases Tbr2-Positive
BPs and Increases Sox2-Positive BPs
To examine if YAP activity is functionally linked to the proliferative
capacity of BPs, we conditionally expressed a constitutively
active YAP (CA-YAP) in BPs of the embryonic mouse neocortex,
which lack proliferative potential and in which YAP expression
normally is very low (Figures 1A, 1D, and 1E). In the CA-YAP,
two serine residues were replaced by alanine (S112A and
S382A), mutations that have been shown to stabilize and to in-
crease the nuclear localization of the YAP protein (Camargo
et al., 2007; Dong et al., 2007; Zhao et al., 2010). The plasmidFigure 2. Conditional CA-YAP Expression in the BP-Genic Lineage of E
BPs and Increases Generation of Sox2-Positive BPs
(A) Left: cartoon showing control (top) and CA-YAP-expressing (bottom) plasm
embryos received tamoxifen (TAM) at E12.5 and E13.5, and the neocortex was
expressing plasmid (C, D, F, and G) followed by analysis at E15.5.
(B, C, E, and F) Double immunofluorescence for RFP (red) and either Tbr2 (B and C
areas in the SVZ that are shown at higher magnification (B0, C0, E0, and F0); arrows
positive (E0 and F0). Images are 1-mm optical sections. Scale bars represent 50 m
(D and G) Quantification of the percentage of RFP-positive nuclei that are Tbr2 po
CA-YAP (black) electroporation. Two images (1-mm optical sections), each of a 2
values obtained were averaged for each embryo. Data are the mean of four emb
Whitney U test).
See also Figures S3 and S5.
1108 Cell Reports 27, 1103–1118, April 23, 2019used for CA-YAP expression (referred to as CA-YAP-expressing
plasmid) contained a strong constitutive promoter (CAGGS)
driving a membrane EGFP and a transcriptional stop sequence,
flanked by loxP sites, followed by the CA-YAP and an internal
ribosome entry site (IRES)-linked nuclear RFP reporter (Figure 2A,
left). Expression of CA-YAP and RFP uponCre-mediated excision
of the floxed EGFP was validated by transfection of HEK293T
cells (Figure S3A). The same plasmid but lacking the CA-YAP
module was used as control (Figure 2A, left). Conditional expres-
sion of CA-YAP predominantly in mouse BPs was achieved by in
utero electroporation (IUE) of the neocortex of E13.5 embryos of
the Tis21-CreERT2 knockin (Btg2tm1.1(cre/ERT2)Wbh) mouse line
(Wong et al., 2015) (Figure 2A right). In embryos of this mouse
line, the expression of tamoxifen-activated Cre follows that of
Tis21, which is specific for BP-genic aRG and BPs (Wong et al.,
2015). We validated that, by analysis of E14.5 embryos, the con-
ditional CA-YAP expression inmouse neocortex by this approach
indeed occurred predominantly in BPs. Specifically, this analysis
revealed that the overwhelming majority of the strongly YAP-
expressing cells were BPs rather than APs (Figures S3B and
S3C). Furthermore, conditional CA-YAP expression by this
approach drove expression of a previously identified YAP target
gene, CTGF (Malik et al., 2015; Zanconato et al., 2015; Zhao
et al., 2008), in BPs 3 days after IUE (Figures S3B and S3D; for
details, see Methods S1).
We first examined the effects of conditional CA-YAP expres-
sion on BP fate by analyzing Tbr2 and Sox2 expression 2 days
after IUE of Tis21-CreERT2 mouse embryos (Figures 2A–2G).
This revealed, among the RFP-positive progeny of the targeted
cells, a marked reduction in the proportion of Tbr2-positive cells
in the VZ and SVZ (Figure 2D) and a striking increase in the pro-
portion of Sox2-positive cells in the SVZ, but not VZ (Figure 2G),
compared to control. Hence, increasing YAP activity in neocor-
tical BPs of embryonic mouse is sufficient to change the expres-
sion of transcription factors that are characteristic of either
neuronal differentiation or proliferation, respectively.
Conditional CA-YAP Expression in Embryonic Mouse
Neocortex Increases the Proliferative Capacity of BPs
Next, we directly examined the potential effects of conditional
CA-YAP expression in embryonic mouse neocortex on BP prolif-
eration using three distinct approaches. First, we performed
immunofluorescence for the cycling cell marker Ki67 2 days (Fig-
ures 3A–3C) and 3 days (Figures S4A–S4C) after IUE. Conditional
CA-YAP expression increased the proportion of Ki67-positivembryonic Mouse Neocortex Decreases Production of Tbr2-Positive
id. Right: flow scheme of experiments. Tis21::CreERT2 heterozygous mouse
subjected to IUE at E13.5 with control plasmid (B, D, E, and G) or CA-YAP-
) or Sox2 (E and F) (cyan), combined with DAPI staining (white). Boxes indicate
indicate selected RFP-positive nuclei that are Tbr2 positive (B0 and C0) or Sox2
m (B, C, E, and F) and 20 mm (B0, C0, E0, and F0).
sitive (D) and Sox2 positive (G) in the VZ and SVZ upon control (light gray) and
00-mm-wide field of cortical wall, per embryo were taken, and the percentage
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cells among the RFP-positive progeny of the targeted cells in the
SVZ 2- to 3-fold (Figures 3D and S4D). Concomitant with this
effect, conditional CA-YAP expression resulted in an altered
distribution of the RFP-positive cells across the various zones
of the cortical wall (Figures S5A–S5C), with a greater relative pro-
portion of these cells in the VZ and a lesser relative proportion in
the IZ and CP (Figure S5D). In terms of absolute progenitor cell
numbers, conditional CA-YAP expression caused a more than
2-fold increase in Ki67- and RFP-positive cells in the VZ and
SVZ (Figure S5E). These data raise the possibility of a relation-
ship between the CA-YAP-induced progenitor proliferation and
the reduced migration of the RFP-positive progeny of the tar-
geted cells beyond the germinal zones to the basal region of
the cortical wall.
Second, we performed immunofluorescence for the mitotic
cell marker phosphovimentin (pVIM) (Figures S4A, S4E, and
S4F). Conditional CA-YAP expression markedly increased the
proportion of pVIM-positive cells among the RFP-positive prog-
eny of the targeted cells in the SVZ (Figure S4G). Consistent with
this, conditional CA-YAP expression also markedly increased
the abundance of mitotic, pVIM-positive BPs (sum of RFP-
positive and RFP-negative basal mitoses) (Figure S4H). Analysis
of the pVIM- and RFP-positive cells remaining in the SVZ three
days after IUE (Figure S4A) for the presence versus absence of
pVIM-positive cell processes (typically a basal process) revealed
no significant difference between the control and conditional
CA-YAP expression (Figure S4I).
Third, we carried out a cell-cycle reentry assay. To this end,
we performed a 50-ethynyl-20deoxyuridine (EdU) pulse labeling
24 h after IUE, followed by Ki67 immunofluorescence 24 h
later (Figure 3E). Given the cell-cycle parameters of Tis21-
GFP-positive APs and BPs at this stage of embryonic mouse
neocortex development (Arai et al., 2011), the latter time inter-
val is sufficient for the incorporated EdU to become inherited
by daughter cells. Thus, EdU- and RFP-positive cells that are
also positive for Ki67 are daughter cells that reentered the cell
cycle (Figure 3E). Using this assay, we found that conditional
CA-YAP expression doubled the cell-cycle reentry of BPs in
the SVZ (Figures 3E–3H). Taken together, the results of these
three lines of investigation demonstrate that conditional
CA-YAP expression in embryonic mouse neocortex increases
BP proliferation.Figure 3. Conditional CA-YAP Expression in the BP-Genic Lineage of Em
Reentry
(A–H) Tis21::CreERT2 heterozygous mouse embryos received tamoxifen (TAM) a
plasmid (B, D, F, and H) or CA-YAP-expressing plasmid (C, D, G, and H) (see Figu
and the neocortex was analyzed at E15.5, as shown in the flow schemes of the
(B and C) Double immunofluorescence for RFP (red) and Ki67 (cyan), combined
higher magnification in (B0) and (C0); arrows indicate selected RFP-positive nucle
(D) Quantification of the percentage of RFP-positive nuclei that are Ki67 positive i
(F and G) Triple (immuno)fluorescence for RFP (red), EdU (cyan), and Ki67 (wh
(F0 and G0); arrows indicate selected RFP- and EdU-positive nuclei that are Ki67
(H) Quantification of the percentage of RFP- and EdU-positive nuclei that are K
electroporation.
(B, C, F, and G) Images are 1-mm optical sections. Scale bars represent 50 mm (B
(D and H) Two images (1-mm optical sections), each of a 200-mm-wide field of co
averaged for each embryo. Data are the mean of four embryos from four separa
See also Figures S3–S5.
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Neocortex Results in Reduced Deep-Layer Neuron and
Increased Upper-Layer Neuron Generation
Given that BPs generate most cortical neurons (Florio and Hutt-
ner, 2014; Lui et al., 2011), we explored the potential conse-
quences of the CA-YAP-induced increase in BP proliferation
for neuron generation in the embryonic mouse neocortex. To
this end, we performed immunostaining for Tbr1, a deep-layer
neuron marker, and Satb2, an upper-layer neuron marker,
4 days after IUE (Figures 4A–4E). Conditional CA-YAP expres-
sion reduced the proportion of Tbr1-positive neurons among
the RFP-positive progeny of the targeted cells in the IZ and
CP to almost half of control (29% versus 44%; Figure 4F) and
caused a small but statistically significant increase in the
proportion of Satb2-positive neurons (from 76% to 87%;
Figure 4G).
Considering that the pool size of the RFP-positive progeny in
the IZ and CP 4 days upon IUE (E13–E17) is not much affected
by the conditional CA-YAP expression compared to control (Fig-
ure S6), these data are consistent with the notion that the
changes in the proportions of specific types of neurons among
the RFP-positive progeny reflect the changes in neuron genera-
tion in embryonic mouse neocortex. Specifically, on the one
hand, the CA-YAP-induced increase in BP proliferation initially
results in a reduced production of deep-layer neurons, because
upon conditional CA-YAP expression, a certain proportion of
mouse BPs have been induced to undergo symmetric prolifera-
tive divisions and hence a lesser proportion of mouse BPs are
available to undergo the symmetric consumptive divisions that
generate neurons. On the other hand, the CA-YAP-induced in-
crease in BP proliferation eventually results in an increased
mouse BP pool size that at later stages of cortical neurogenesis
gives rise to more upper-layer neurons.
Pharmacological Inhibition of YAP Activity Reduces
Mitotic BP Abundance in Embryonic Ferret and Fetal
Human Neocortex
Having established that mimicking a ferret- or human-like
expression of active YAP in BPs of embryonicmouse (i.e., lissen-
cephalic) neocortex suffices to increase their proliferation, we
next investigated whether the presence of active YAP in BPs of
developing ferret and human (i.e., gyrencephalic) neocortex isbryonicMouse Neocortex Promotes BP Proliferation and Cell Cycle
t E12.5 and E13.5, the neocortex was subjected to IUE at E13.5 with control
re 2A), embryos did not (B–D) or did (F–H) receive a single EdU pulse at E14.5,
experiments in (A) and (E), respectively.
with DAPI staining (white). Boxes indicate areas in the SVZ that are shown at
i that are Ki67 positive.
n the VZ and SVZ upon control (light gray) and CA-YAP (black) electroporation.
ite). Boxes indicate areas in the SVZ that are shown at higher magnification
positive.
i67 positive in the VZ and SVZ upon control (light gray) and CA-YAP (black)
, C, F, and G) and 20 mm (B0, C0, F0, and G0).
rtical wall, per embryo were taken, and the percentage values obtained were
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a necessary requirement for their proliferation. To this end, we
applied an inhibitor of YAP, verteporfin (Brodowska et al.,
2014; Liu-Chittenden et al., 2012; Song et al., 2014; Wang
et al., 2015), in an ex vivo free-floating tissue (FFT) culture system
(Schenk et al., 2009) using E33–E34 ferret and 11–13 wpc human
neocortical tissue (Figure 5). Verteporfin is a small molecule that
inhibits the association of YAP with TEAD transcription factors
and thereby prevents the expression of genes linked to cell pro-
liferation (Liu-Chittenden et al., 2012).
Treatment of embryonic ferret and fetal human neocortical
FFT cultures with 1 mM verteporfin for 48 h decreased the abun-
dance of basal mitoses, as identified by phospho-histone H3
(PH3) immunofluorescence (Figures 5A and 5C), 4-fold and
2-fold, respectively (Figures 5B and 5D). The time period of
48 h corresponds roughly to the length of one cell cycle of BPs
in ferret (Turrero Garcı´a et al., 2016) and human (Hansen et al.,
2010; Mora-Bermu´dez et al., 2016) neocortex, and BPs were
quantified at mitosis (i.e., at the end of their cell cycle). The ver-
teporfin data therefore imply that the decrease in BP abundance
must have occurred largely in the BPs themselves (as opposed
to in APs that then gave rise to BPs).
Upon verteporfin treatment of embryonic ferret and fetal
human neocortical FFT cultures, mitotic AP levels did not
show a statistically significant decrease (Figures 5B and 5D),
although in the case of ferret, the trend of a decrease could
be observed (Figure 5B). A possible explanation why there
was no decrease in human mitotic AP levels upon verteporfin
treatment may be that the length of the human AP cell cycle
did not allow manifestation of a decrease in mitotic AP levels
within the 48-h period between addition of verteporfin and
analysis.
Dominant-Negative YAP Expression ReducesMitotic BP
Abundance in Embryonic Ferret Neocortex
We sought to obtain corroborating in vivo evidence for an essen-
tial role of YAP activity in BP proliferation in developing gyrence-
phalic neocortex. To this end, we used a dominant-negative YAP
construct (DN-YAP) to block its transcriptional co-activator
function (Nishioka et al., 2009; Sudol et al., 2012) (see STAR
Methods for details). In this DN-YAP construct, the transactiva-
tion domain ofmouse YAP is replacedwith the engrailed domain,
a Drosophila repressor of transcription (Nishioka et al., 2009),
and nuclear localization of DN-YAP is ensured by replacing
YAP serine 112 with alanine (Hao et al., 2008; Zhao et al.,
2007). Forced expression of DN-YAP creates multiple copies
of DN-YAP that outcompete endogenous wild type YAP (wtYAP)
in binding to TEAD transcription factors, which causes downre-Figure 4. Conditional CA-YAP Expression in the BP-Genic Lineage of Em
Neurons and Increases the Production of Upper-Layer Neurons
(A) Flow scheme of experiments. Tis21::CreERT2 heterozygous mouse embryos re
to IUE at E13.5 with control plasmid (B, D, F, and G) or CA-YAP-expressing plas
(B–E) Double immunofluorescence for RFP (red) and either Tbr1 (B and C) or Satb2
sections. Scale bars, 50 mm.
(F and G) Quantification of the percentage of RFP-positive nuclei that are Tbr1 po
(CP) upon control (light gray) and CA-YAP (black) electroporation. Two images (1
were taken, and the percentage values obtained were averaged for each embryo.
is shown; *p < 0.05 (Mann-Whitney U test).
See also Figure S6.
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et al., 2009; Zanconato et al., 2015). We chose embryonic ferret
neocortex to examine the effects of DN-YAP expression on BP
proliferation.
We performed IUE of ferret embryos to deliver the DN-YAP
construct into the developing ferret neocortex (Kawasaki
et al., 2012, 2013). Specifically, we co-electroporated the ferret
dorsolateral neocortex with either CAGGS-empty vector plus
CAGGS-EGFP or with CAGGS-DN-YAP plus CAGGS-EGFP.
IUE was performed at E33, the stage that corresponds to
mid-neurogenesis in the ferret. Ferret embryos were harvested
2 days later, at E35, and mitotic BPs were quantified. Given the
length of the cell cycle of ferret BPs (Turrero Garcı´a et al., 2016),
the 2-day period between IUE and analysis (Figure 6A) should
suffice for the targeted BPs to complete their cell cycle and
enter mitosis. To confirm the expression of DN-YAP, we per-
formed immunostaining using a YAP antibody that recognizes
both endogenous YAP and DN-YAP and compared the level
of YAP immunoreactivity in GFP-positive cells upon DN-YAP
expression to that of control. Upon DN-YAP expression,
many of the GFP-positive cells showed a higher level of YAP
immunoreactivity, especially in the SVZ, suggesting that the
DN-YAP was successfully expressed in BPs (Figure 6B;
compare bottom and top rows).
Analysis of GFP-positive mitoses, identified by PH3 immu-
nofluorescence, revealed that expression of DN-YAP drasti-
cally decreased the abundance of mitotic BPs (Figures 6B
and 6C). Similar results were obtained by quantitation of
GFP- and pVIM-positive basal mitoses (Figures 6D and 6E).
In contrast, DN-YAP expression caused only a small decrease
in the abundance of GFP- and PH3-positive mitotic APs (Fig-
ures 6B and 6C) and no statistically significant decrease in the
abundance of GFP- and pVIM-positive mitotic APs (Figures
6D and 6E).
There are two main types of BPs: (1) those lacking processes
at mitosis (i.e., bIPs) and (2) those bearing radial processes at
mitosis (i.e., bRG) (Fietz et al., 2010; Kelava et al., 2012; Reillo
et al., 2011). To examine whether any of these two types of
BPs are preferentially affected by DN-YAP expression, we
analyzed the processes as revealed by pVIM staining in GFP-
positive mitotic BPs in the SVZ. We observed a similar decrease
in process-lacking and process-bearing BPs (Figure 6F), which
suggests that the effect of DN-YAP expression is nonselective
with regard to the BP population type, affecting equally bIPs
and bRG.
Given that conditional CA-YAP expression in embryonic
mouse neocortex resulted in a specific increase in Sox2-positivebryonicMouse Neocortex Decreases the Production of Deep-Layer
ceived tamoxifen (TAM) at E12.5 and E13.5, and the neocortex was subjected
mid (C and E–G) (see Figure 2A), followed by analysis at E17.5.
(D and E) (cyan), combinedwith DAPI staining (white). Images are 1-mmoptical
sitive (F) and Satb2 positive (G) in the intermediate zone (IZ) and cortical plate
-mm optical sections), each of a 200-mm-wide field of cortical wall, per embryo
Data are the mean of four embryos from four separate litters. The mean ± SEM
A B
C D
Figure 5. Inhibition of YAP Activity by Verteporfin Reduces Mitotic BP Levels in Embryonic Ferret and Fetal Human Neocortex
(A–D) Ferret E33–E34 (A and B) and human 11–13 wpc (C and D) neocortex was incubated for 48 h in FFT culture in the absence (control, top rows in A and C and
open circles in B and D) or presence (bottom rows in A and C and filled circles in B and D) of 1 mM verteporfin, followed by analysis.
(A and C) Immunofluorescence for PH3 (magenta), combined with DAPI staining (blue), upon control (top rows) and verteporfin (bottom rows) treatment. Images
are 1-mm optical sections. Scale bars, 100 mm.
(B and D) Quantification of the number of APs and BPs in mitosis, as revealed by PH3 immunofluorescence, per microscopic field (400-mm-wide field of cortical
wall), upon control (open circles) and verteporfin (filled circles) treatment. Five to eight images (1-mm optical sections) per either ferret embryo (B) or human fetus
(D) were taken, and the values obtained were averaged for each embryo-fetus. Data are themean of three ferret embryos from three separate litters (B) and of four
human fetuses (D). Error bars indicate SD; *p < 0.05 (Mann-Whitney U test).BPs (Figure 2G), we explored whether inhibition of YAP activity in
embryonic ferret neocortex would affect the Sox2-positive pool
of BPs in the SVZ. Indeed, DN-YAP expression reduced the pro-
portion of Sox2-positive BPs among the GFP-positive progeny
of the targeted cells in the SVZ (Figures 6G and 6H).
Disruption of YAP Expression in Fetal Human Neocortex
Reduces BP Abundance
We complemented the data obtained upon DN-YAP expression
in embryonic ferret neocortex by disrupting the expression of the
YAP gene in fetal human neocortical tissue using CRISPR-Cas9
technology. Human neocortical tissue from 12 to 14 wpc fetuses
was electroporated with either CAGGS-EGFP plus a CRISPR-
Cas9 control plasmid or a GFP-expressing plus YAP-disrupting
plasmid. Analyses after 72 h in FFT culture revealed that upon
disruption of YAP expression, many of the targeted delaminated
cells, as identified by GFP immunofluorescence, showed a lower
level of YAP immunoreactivity than control delaminated cells(Figure 7A). This allowed us to compare the proportion of cycling
cells, identified by proliferating cell nuclear antigen (PCNA)
immunofluorescence, among the targeted delaminated (i.e.,
GFP+) cells (that is, BP abundance) upon control electroporation
and disruption of YAP expression (Figure 7B). This comparison
revealed that the disruption of YAP expression significantly
decreased BP abundance (Figure 7C). Hence, YAP expression
in BPs is required to maintain their normal level in fetal human
neocortex.
Taken together, our data using verteporfin administration,
DN-YAP expression, and disruption of YAP expression indicate
that YAP activity is necessary for the proliferation of BPs in devel-
oping gyrencephalic neocortex in vivo.
Our observation that YAP expression and Tbr2 expression
in ferret and human BPs are mutually exclusive (Figure 1K)
precluded the development of a BP-specific YAP knockout
approach based on the specificity of the Eomes-EOMES
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AB
C
Figure 7. CRISPR-Cas9-Mediated Disrup-
tion of YAP Expression in Fetal Human
Neocortical Tissue Reduces BP Abundance
(A–C) Human 12- to 14-wpc neocortical tissue was
electroporated ex vivo with either GFP-expressing
plus control plasmids (A and B, left; and C) or a
GFP-expressing plus YAP-disrupting plasmid (see
STAR Methods) (A and B, right; and C) and then
incubated for 72 h in FFT culture, followed by
analysis.
(A) Double immunofluorescence for GFP (green)
and YAP (white) upon control electroporation (left)
and YAP gene disruption (right). Delaminated
cells, as identified by GFP immunofluorescence,
that exhibit YAP expression in the control condi-
tion (left) and show reduced YAP expression upon
YAP gene disruption (right) are indicated by red
dotted lines. Images are 1.2-mm optical sections.
Scale bar, 10 mm.
(B) Double immunofluorescence for GFP (green)
and PCNA (magenta) upon control electroporation
(left) and YAP gene disruption (right). Delaminated
cells, as identified by GFP immunofluorescence,
that exhibit PCNA expression in the control
condition (left) and show reduced PCNA expression upon YAP gene disruption (right) are indicated by white dashed lines. Images are 1.2-mm optical sections.
Scale bar, 10 mm.
(C) Quantification of the percentage of delaminated GFP+ cells that are overtly PCNA positive (PCNA+) upon control electroporation (open bar) and YAP gene
disruption (YAP Y, solid bar). Control: data are the mean of four electroporated tissues (n = 4) from two fetus (14 wpc and 12 wpc), with a total of 88 delaminated
GFP+ cells counted. For YAP Y, data are the mean of three electroporated tissues (n = 3) from three fetus (14 wpc, 13 wpc, and 13 wpc), with a total of
118 delaminated GFP+ cells counted. Error bars indicate SEM; *p < 0.05 (non-paired Student’s t test).DISCUSSION
The present study demonstrates a crucial role of YAP, the central
effector of the Hippo signaling pathway, in the development and
evolution of the mammalian neocortex. Specifically, our findings
advance our understanding of cNPC activity in cortical develop-
ment and its differences across mammals with regard to two keyFigure 6. Expression of a DN-YAP in Embryonic Ferret Neocortex Red
(A) Left: cartoon showing the EGFP-expressing plasmid plus the control plasmid
(bottom).
(B–H) Right: flow scheme of experiment. Ferret neocortex was electroporated at E
left; D0 and E–G, left; and G0 and H) or GFP-expressing plus DN-YAP-expressing
followed by analysis at E35.
(B) Triple immunofluorescence for YAP (white), GFP (green), and PH3 (magenta)
shown at higher magnification in B0 and B00; arrows indicate selected GFP-positi
(C) Quantification of the number of GFP-positive APs and BPs in mitosis, as reve
cortical wall) upon control (open circles) and DN-YAP (filled circles) electroporatio
values obtained were averaged for each embryo. The data show the averaged v
(D) Double immunofluorescence for GFP (green) and pVIM (magenta). Boxes indic
in (D0 ) indicate selected GFP-positive cells that are pVIM positive; arrowheads in
(E) Quantification of the number GFP-positive APs and BPs in mitosis, as reveal
cortical wall) upon control (open circles) andDN-YAP (filled circles) electroporation
obtained were averaged for each embryo. The data show the averaged values fo
(F) Quantification of the number of process-lacking (left) and process-bearing (righ
permicroscopic field (200 mm-wide field of cortical wall) upon control (light gray) an
(control, 30; DN-YAP, 29) from five ferret embryos.
(G) Double immunofluorescence for GFP (green) and Sox2 (G) (magenta). Boxes
arrows indicate selected GFP-positive nuclei that are Sox2 positive.
(H) Quantification of the percentage of GFP-positive cells in the SVZ that are Sox2
Six images (1-mmoptical sections), each of a 200-mm-wide field of cortical wall, we
for each embryo. Data are the mean of five ferret embryos from one litter.
(B, B0, B00, D, D0, D00, G, G0, and G00) Images are 1-mm optical sections. Scale bar
(C, E, and H) The mean ± SD is shown; *p < 0.05, **p < 0.01 (Mann-Whitney U teaspects. First, YAP activity is shown to be necessary and suffi-
cient to maintain the proliferative capacity of BPs at levels
typically seen in developing gyrencephalic neocortex. Second,
differences in YAP activity in BPs between embryonic mouse,
which develops a lissencephalic neocortex, on the one hand,
and embryonic ferret and fetal human, which develop a gyrence-
phalic neocortex, on the other hand, are shown to contribute to,uces Mitotic BP Levels
(top) and the EGFP-expressing plasmid plus the DN-YAP-expressing plasmid
33 with either GFP-expressing plus control plasmids (B, top row; B0, C, and D,
plasmids (B, bottom row; B00, C, and D, right; D00 and E–G, right; and G00 and H),
, combined with DAPI staining (blue). Boxes indicate areas in the SVZ that are
ve cells that are PH3 positive.
aled by PH3 immunofluorescence, per microscopic field (200-mm-wide field of
n. 6–15 images (1-mm optical sections) per ferret embryo were taken, and the
alues for five ferret embryos from one litter.
ate areas in the SVZ that are shown at higher magnification (D0 and D00); arrows
(D00) indicate selected pVIM-positive nuclei that are GFP negative.
ed by pVIM immunofluorescence, per microscopic field (200-mm-wide field of
. Six images (each a 5-mmz stack) per ferret embryowere taken, and the values
r five ferret embryos from one litter.
t) GFP-positive mitoses in the SVZ, as revealed by pVIM immunofluorescence,
d DN-YAP (black) electroporation. Data are themean ofmultiple fields counted
indicate areas in the SVZ that are shown at higher magnification (G0 and G00);
positive upon control (open circles) and DN-YAP (filled circles) electroporation.
re taken per ferret embryo, and the percentage values obtained were averaged
s, 50 mm.
st).
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if not underlie, the differences in BP proliferative capacity across
these species. Three aspects of our findings deserve particular
consideration.
Differential YAP Expression between the VZ and SVZ
across Species
Previous reports on the role of YAPwere confined tomouse brain
development and concentrated on APs (Cappello et al., 2013;
Lavado et al., 2013, 2014; Saito et al., 2018). In contrast to these
reports, the present study is focused on BPs and in this context
has compared YAP expression and activity in the SVZ versus VZ
of developing neocortex of three mammals exhibiting a different
extent of neocortex expansion: mouse, ferret, and human. Our
demonstration that in species in which BPs exhibit significant
proliferative capacity, YAP expression and activity are well
detectable not only in the VZ but also in the SVZ has at least
two implications. First, to the best of our knowledge, these
data constitute the first report of YAP protein expression in the
iSVZ and oSVZ of developing neocortex. Second, the present
findings suggest that the role of YAP, and hence Hippo signaling,
in the proliferation and consequently the pool size of cNPCs is far
more widespread than previously assumed.
YAP Is a Putative Downstream Target of Sox2 in BPs
The co-expression of active YAP with Sox2 in ferret and human
BPs suggests an interesting mechanistic scenario regarding the
regulation of YAP expression and, consequently, activity.
Recently, it was shown that Sox2 directly drives the expression
of YAP in progenitors of the osteo-adipo lineage (Seo et al.,
2013). Given that mouse BPs exhibit lower Sox2 expression
than mouse APs whereas ferret and human BPs maintain a
Sox2 expression similar to APs (Figures 1A–1C), our results raise
the possibility that YAP expression in ferret and human prolifer-
ative BPs is driven by Sox2. Furthermore, while the ability of YAP
to activate transcription is known to be decreased by phosphor-
ylation via upstream Hippo signaling kinases such as Nf2 and
Wwc1 (Yu et al., 2015), it was recently reported that in cancer
stem cells, Sox2 represses transcription of the NF2 and WWC1
genes, which in turn increased YAP activity (Basu-Roy et al.,
2015). Our finding of increased YAP activity in proliferative BPs
of developing gyrencephalic neocortex could therefore be
explained by Sox2 in these cells repressing NF2 and WWC1.
BP Fate Switch upon Conditional YAP Expression
However, our data not only are consistent with the notion that in
ferret and human BPs Sox2 positively regulates YAP expression
levels and activity but also indicate that forced YAP expression in
mouse BPs, directly or indirectly, results in increased Sox2
expression and decreased Tbr2 expression. In other words,
the present approach of conditionally expressing CA-YAP in
the mouse Tis21-positive BP lineage induced a BP fate switch
from neurogenic to proliferative. This in turn led to an expansion
of the BP pool, which eventually resulted in an increased gener-
ation of upper-layer neurons. Hence, increasing YAP activity in
BPs is sufficient to induce features that are hallmarks of an
expanded neocortex, as characteristically observed in gyrence-
phalic mammals (Florio and Huttner, 2014; Lui et al., 2011). This,
together with our finding that inhibiting YAP activity in BPs of1116 Cell Reports 27, 1103–1118, April 23, 2019developing ferret and human neocortex reduced their abun-
dance, in turn leads us to conclude that an increase in YAP
activity in BPs of developing neocortex likely was a major
contributor to its evolutionary expansion.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics
All animal experiments (mice and ferrets) were performed in accordance with the German Animal Welfare legislation (‘‘Tierschutzge-
setz’’). All procedures regarding the animal experiments were approved by the Governmental IACUC (‘‘Landesdirektion Sachsen’’)
and overseen by the Institutional Animal Welfare Officer(s). The license numbers concerning the experiments with mice are:
Untersuchungen zur Neurogenese in Ma¨useembryonen TVV2015/05 (in utero electroporation, tamoxifen, EdU) and 24–9168.24-9/
2012-1 (tissue collection without prior in vivo experimentation). The license number concerning the experiments with ferrets is:
Untersuchungen zur Neurogenese in Frettchen’’ (TVV 2015/02) issued by ‘‘Landesdirektion Sachsen.’’
Mice
To characterize YAP expression E13-14 mouse embryos (C57BL/6JOlaHsd) were used. The sex of embryos was not determined
because the male versus female phenotype is not yet fully developed at the developmental stage concerned. For electroporatione2 Cell Reports 27, 1103–1118.e1–e6, April 23, 2019
E13 Tis21-CreERT2+/ heterozygous mouse embryos were used. These were obtained by crossing C57BL/6JOlaHsd females and
Tis21-CreERT2+/+ males (Wong et al., 2015). Mice were crossed and kept under strict pathogen-free conditions in the animal facility
of the Max Planck Institute of Molecular Cell Biology and Genetics.
Ferrets
Normally pigmented pregnant female sable ferrets (Mustela putorius furo) were purchased fromMarshall BioResources (North Rose,
NY, USA). They were delivered and housed in the animal facility of the Max Planck Institute of Molecular Cell Biology and Genetics. In
utero electroporation and verteporfin treatment was performed on E33 embryos. The sex of embryos was not determined because
the male versus female phenotype is not yet fully developed at the developmental stage concerned.
Human fetal tissue
Human fetal brain tissue was obtained from two sources. First, from the Klinik und Poliklinik f€ur Frauenheilkunde und Geburtshilfe,
Universita¨tsklinikum Carl Gustav Carus of the Technische Universita¨t Dresden, following elective pregnancy termination and
informed written maternal consents (see Methods S1), and with approval of the local University Hospital Ethical Review Committees.
The age of a 12 wpc fetus (n = 1) was assessed by ultrasound measurements of crown-rump length and other standard criteria of
developmental stage determination. The second source was the Human Developmental Biology Resource (HDBR). This human fetal
brain tissuewas provided by the JointMRC/WellcomeTrust (grant #MR/R006237/1) HumanDevelopmental BiologyResource (www.
hdbr.org). The HDBR provided fresh tissue from fetuses aged 11-14 wpc, (11 wpc, n = 4; 12 wpc, n = 3; 13 wpc, n = 4; wpc 14, n = 2).
Due to protection of data privacy neither gender identity nor sex of the human fetuses of which neocortex tissue was obtained can be
reported. Neither gender identity nor sex of the human fetuses is likely to be of relevance for the results obtained in the present study.
Human fetal brain tissuewas dissected in 1x PBS and used immediately for culture or fixation (as indicated) when obtained fromDres-
den. When obtained from HDBR, tissue was dissected and shipped in Hibernate E media (GIBCO A1247601). Upon arrival, all tissue
was cultured in slice culture medium (SCM, see section on ex vivo FFT cultures) for 2-3 h prior to any further manipulation. All tissue
was fixed for at least 24 h at 4C in 4% paraformaldehyde in 120 mM phosphate buffer (pH 7.4) (referred to in short as 4% PFA).
METHOD DETAILS
YAP DNA constructs
Mouse wtYAP isoform 1 cDNA clone (IMAGE 4239820) was obtained from Source Bioscience. Restriction enzyme sites, SalI, were
adapted to the 50 and 30 ends of wtYAP by PCR. wtYAP was digested by SalI and subcloned to the pCR2.1-TOPO-TA vector
(Invitrogen), creating an intermediate, non-expressing vector pTOPO-mouse-wtYAP. The destination vector pCAGGS-LoxP-
Gap43-GFP-LoxP-IRES-nRFP (Wong et al., 2015) was used as control plasmid and used to obtain the CA-YAP plasmid. To this
end, it was digested by XhoI, and pTOPO-mouse-wtYAP was digested by SalI to obtain linearized wtYAP DNA. The opened desti-
nation vector (pCAGGS–LoxP–Gap43-GFP–LoxP–IRES–nRFP) and the linearized wtYAP DNA were purified by 2% agarose gel
electrophoresis and ligated together to yield pCAGGS–LoxP–Gap43-GFP–LoxP–wtYAP–IRES–nRFP. This plasmid was then used
to generate the CA-YAP-carrying plasmid (pCAGGS–LoxP–Gap43-GFP–LoxP–CA-YAP–IRES–nRFP) by replacing two serine
residues, YAP-S112 and YAP-S382, with alanine residues, by PCR point mutagenesis.
To obtain the DN-YAP plasmid, pcDNA3.1-pA83-dnYAP (RBD12195) was obtained from the RIKEN BRC through the National
Bio-Resource Project of the MEXT, Japan. In pcDNA3.1-pA83-dnYAP, YAP-S112 is replaced with alanine, and the transactivation
domain of mouse YAP is replaced with the engrailed repression domain from Drosophila. pcDNA3.1-pA83-dnYAP was subcloned
into the pCR2.1-TOPO-TA vector (Invitrogen) using PCR and adding BamHI sites to the 50 and 30 ends of dnYAP, creating an inter-
mediate, non-expressing vector pTOPO-mouse-DN-YAP. The destination vector pCAGGS-empty (Niwa et al., 1991) was used as
control plasmid and used to obtain the DN-YAP plasmid. To this end, it was digested by BglII, and pTOPO-mouse-DN-YAP was
digested by BamHI to obtain linearized DN-YAP DNA. The opened destination vector (pCAGGS-empty) and the linearized DN-YAP
DNA were purified by 2% agarose gel electrophoresis and ligated together to yield pCAGGS-DN-YAP.
HEK293T cell transfection
HEK293T cells were grown in DMEM (GIBCO) supplemented with 10% fetal calf serum and containing 1% penicillin/streptomycin
(GIBCO 15140122) at 37C in an atmosphere of 5%CO2 / 95% air. The transfection was performed with Lipofectamine 2000 reagent
(Invitrogen). The day before transfection, cells were plated on a 24-well plate, 105 cells per well, in the above cell culture medium.
Cells were either lipofectamine transfected with CA-YAP only (600 ng per well) or co-transfected with CA-YAP and CAGGS-Cre
(each 600 ng per well). After 48 h, cells were harvested and fixed in 4% PFA for 20 min. The cells were washed with 1x PBS and
processed for further analysis within 24 h.
Tamoxifen preparation and administration
Tamoxifen powder, 200 mg, was dissolved in 10 mL of corn oil (Sigma, T-5648) under constant stirring atz40C. Tamoxifen was
administered to trigger activation of Cre recombinase in Tis21::CreERT2 ± mouse embryos. Pregnant mice received tamoxifen
(2 mg, 0.1 ml) orally by gavage at E12.5, i.e., one day before IUE, and once on the day of IUE (E13.5).Cell Reports 27, 1103–1118.e1–e6, April 23, 2019 e3
In utero electroporation of mice
Tamoxifen-treated pregnant mice carrying E13.5 embryos were anesthetized using initially 5% isoflurane (Baxter, HDG9623),
followed by 2%–3% isoflurane during the IUE procedure. Endotoxin-free plasmids (Control, pCAGGS–LoxP–Gap43-GFP–LoxP–
IRES–nRFP; CA-YAP, pCAGGS–LoxP–Gap43-GFP–LoxP–CA-YAP–IRES–nRFP) were mixed on the day of surgery with Fast Green
(Sigma, 0.25% final concentration) to a final plasmid concentration of 2 mg/ml in 1x PBS. Using a borosilicate microcapillary (Sutter
instruments, BF120-69-10) the DNA/Fast Greenmixture was intraventricularly injected, which was followed by six 50-msec pulses of
30 V at 1 s intervals (BTX genetronics Inc., 45-0052INT), using a 3-mm diameter electrode (BTX genetronics Inc., 45-0487). After the
IUE, the uterus was placed back into the abdominal cavity, and the peritoneum was sutured (VICRYL 5-0, V493H). Abdominal skin
was closedwith clips and animal received 100 ml of painkiller (Rimadyl 1mg/ml). Pregnantmicewere sacrificed by cervical dislocation
at the indicated time points (E14.5-E17.5), and embryonic brains were dissected and fixed in 4% PFA, overnight at 4C.
Verteporfin treatment of ferret and human neocortex in ex vivo free-floating tissue culture
An ex vivo free-floating tissue (FFT) culture system, adapted and modified from Long et al. (2018) and Schenk et al. (2009), was used
to perform verteporfin treatment of embryonic ferret and fetal human neocortex tissue. E33 ferret brains were dissected, meninges
removed, and the two hemispheres separated. Fetal human neocortex tissue of 11-13 wpc was cut into 2000-2500 mm-thick
pieces (tangential dimension). Tissue was cultured in a whole-embryo culture incubator (Ikemoto RKI) in a rotating flask with
1.5 mL of SCM (for composition, see below), and incubated at 37C in the presence of a humidified atmosphere consisting of
40%O2 / 5% CO2 / 55% N2, with continuous rotation at 26 rpm. Control flasks contained 10 ml of DMSO (Dimethyl sulfoxide, Sigma,
472301) added to the 1.5 mL of SCM. Verteporfin flasks contained 1 mM of verteporfin (Verteporfin, Sigma, SML0534) dissolved in
10 ml of DMSO, added to the 1.5mL of SCM. FFT cultures were carried out for 48 h, with one change of SCM (containing either DMSO
or DMSO plus verteporfin) after 24 h. After 48 h of FFT culture, tissue was fixed in 4% PFA overnight at 4C.
The SCM medium used for FFT cultures contained: 84 mL of Neurobasal medium (GIBCO, 21103049) supplemented with either
10 mL of rat serum (ferret and human cultures) or 10 mL of 5x KnockOUTTM Serum Replacement (for human cultures, GIBCO,
10828028), 1 mL GlutaMAXTM (100x), 1 mL penicilin/streptomycin (100x) (GIBCO, 15140122), 1 mL N-2 (100x) (GIBCO,
17502048), 2 mL B-27 (50x) (GIBCO, 17504044) and 1 mL of 1 M HEPES-NaOH, pH 7.2, to yield a final volume of 100 ml.
In utero electroporation of ferrets
In utero electroporation of E33 ferret embryos was performed as originally established (Kawasaki et al., 2012, 2013), with the mod-
ifications indicated below. Pregnant ferrets (with embryos at E33) were kept fasted for at least 3 h before the surgery and placed in the
narcosis box with 4% isoflurane. Subsequently, they were positioned on the operation table and attached to the narcosis mask with
3% isoflurane and injected subcutaneously with analgesic (0.1 mL Metamizol, 50 mg/kg), antibiotic (0.13 mL Synulox, 20 mg/kg or
0.1 mL amoxicilin, 10 mg/kg) and glucose (10 mL 5%glucose solution). The ferret bellies were then shaved, sterilized with iodide and
surgically opened. Then, the uterus was exposed. As the ferret uterus is pigmented, a transmitted light source was used for the visu-
alization of embryos. Embryos were injected intraventricularly with a solution containing 0.1% Fast Green (Sigma) in sterile 1x PBS,
2 mg/ml of one of the endotoxin-free plasmids (CTRL-empty or DN-YAP) as indicated. To visualize electroporated cells, CTRL and
DN-YAP plasmids were co-electroporated with CAGGS-EGFP (1 mg/ml), using a 5-mm diameter electrode (BTX genetronics Inc.,
45-0489). Electroporations were performed with six 50-msec pulses of 100 V at 1 s intervals. Subsequently, the uterus was placed
back in the peritoneal cavity, muscle layer with the peritoneum were sutured (VICRYL 4-0), after which the skin was sutured intracu-
taneously. Animals were carefully monitored until they woke up and then underwent postoperative care for the following 3 days.
Pregnant females received subcutaneous injections of 15 mL of 5% glucose and the painkiller Metamizol (50 mg/kg, WDT,
99012) three times per day.
The embryos were obtained by cesarean section at E35, and the cerebral cortex was dissected and fixed in 4% PFA overnight at
4C. To this end, themother ferrets underwent a second surgery that followed the same pre-operative care, anesthesia and analgesia
as the first surgery. The sutures from the first operation were removed and the uterus exposed, after which the embryos were
removed by a caesarian section. Subsequently a complete hysterectomy was performed, after which the muscle layer with perito-
neum and skin were sutured and the animal underwent the same post-operative care as after the first surgery. Animals were kept at
the BMS of the MPI-CBG for at least two weeks after the second surgery after which they were donated for adoption.
Human tissue electroporation
Ex vivo electroporation of fetal human neocortical tissue (12-14 wpc) was performed as described previously (Kalebic et al., 2019).
Briefly, neocortical tissue was placed in an electroporation chamber filled with sterile PBS, followed by addition to the apical side of
the tissue of either the mixture of plasmids (pCAGGS-EGFP at 1.8 mg/ml together with the LacZ CRISPR/Cas9 plasmid (Kalebic et al.,
2016) at 1.8 mg/ml) for control, or the YAP CRISPR/Cas9 KO plasmid (Santa Cruz Biotechnology, sc-400040; encoding Cas9, three
gRNAs, and EGFP; at 1.8 mg/ml), all in PBS containing 0.1% Fast Green (Sigma). Immediately thereafter, electroporations were
performed (36 V, ten 50 msec pulses with 1 s intervals), with the cathode on the apical side and the anode on the basal side of
the tissue. After electroporation, the tissue was washed in PBS. The electroporated tissue was incubated in FFT culture for 72 h,
followed by fixation in 4% PFA and processing for immunostaining.e4 Cell Reports 27, 1103–1118.e1–e6, April 23, 2019
EdU labeling
To analyze cell-cycle re-entry, one pulse of EdU was administered by intraperitoneal injection of 0.1 mL of EdU (1 mg/ml) into preg-
nant mice carrying E14.5 embryos, 24 h before the animal was sacrificed. At this stage of mouse cortical neurogenesis, the average
length of the sum of S-phase, G2 plus M-phase of Tis21-GFP–positive APs and BPs isz4 h andz5 h, respectively (Arai et al., 2011).
Hence, the time period of 24 h between the EdU pulse and the analysis is sufficient for the incorporated EdU to become inherited by
daughter cells. To determine whether or not an EdU-labeled daughter-cell (see below for EdU detection) derived from an RFP-
expressing mother cell re-entered the cell-cycle, Ki67 immunofluorescence was performed as is described below. EdU detection
was performed on cryosections. After the incubation with secondary antibodies (see below), the tissue was fixed again, for
20 min with 4% PFA. EdU detection was carried out following the protocol of the Click-iT EdU kit with Alexa Fluor 647 (Invitrogen),
as described previously (Arai et al., 2011).
Immunofluorescence on fixed cells and tissues
Transfected HEK293T cells were incubated with trypsin (GIBCO 25300054) (5 min), harvested, sedimented (300 x g), resuspended in
1x PBS, and fixed in 4% PFA for 10 min at room temperature. Cells were permeabilized with 0.3% Triton X-100 in 1x PBS for 10 min,
followed by quenching in 0.1M glycine in 1x PBS for 10min. Primary antibodies were incubated for 2 h at room temperature, followed
by incubation with secondary antibodies for 1 h, all in 1x PBS containing 0.2% gelatin, an additional 300 mM NaCl, and 0.3% Triton
X-100 (PGNT buffer). Coverslips with the fixed, permeabilized and immunostained cells were washed with 1x PBS and mounted on
glass slides using Mowiol.
Embryonic mouse and ferret brain and fetal human brain tissues fixed in 4% PFA were washed in 1x PBS, immersed in 30%
sucrose, and kept overnight in sucrose at 4C on a rocking platform. The sucrose-soaked tissue was embedded with Tissue-Tek
solution (O.C.T., Sakura Finetek) and frozen at –20C. Tissue was sectioned on a cryostat (20-mmcryosections). Frozen cryosections
were rehydrated in 1x PBS. To be able to reliably detect nuclear epitopes, we routinely carried out an antigen retrieval protocol as
follows. Cryosections were heated in 0.01MNa-citrate pH 6.0 at 70C for 45-60min. After cooling to room temperature cryosections
were permeabilized with 0.3% Triton X-100 in the 1x PBS for 30 min and quenched in 0.1 M glycine in 1x PBS for 30 min. Primary
antibodies were incubated overnight at 4C, followed by incubation with secondary antibodies for 2 h, all in PGNT buffer. After several
washes in PGNT buffer and then in 1x PBS, cryosections were mounted on glass slides using Mowiol.
Total YAP versus phospho-YAP
For the comparison of total YAP versus phospho-YAP immunoreactivity and the determination of nuclear dephospho-YAP levels
(Figure S2A and B), immunofluorescence was performed as follows. Cryosections of fixed mouse, ferret and human neocortex of
the indicated developmental stages (1-2 cryosections per embryo/fetus) were incubated overnight at 4C with two primary anti-
bodies against YAP, a mouse monoclonal antibody recognizing total YAP (Abcam, ab56701, 1:100) and a rabbit polyclonal antibody
recognizing only YAP phosphorylated at serine127 (phospho-YAP, Cell Signaling, 4911, 1:100), and a polyclonal goat antibody
against Sox2 (R&D Systems, AF2018, 1:100), followed by incubation with the respective appropriate secondary antibodies, anti-
mouse-Alexa Fluor 488, anti-rabbit Alexa Fluor 555 and anti-goat Alexa Fluor 647 (Molecular Probes), for 2 h at room temperature.
After a series of washes in 1x PBS, sections were mounted on glass slides using Mowiol.
For the quantification of YAP immunoreactivity, one image per cryosection was taken and 30 randomly selected Sox2-positive
nuclei in the SVZ were scored per cryosection. For both, the total YAP channel and the phospho-YAP channel, immunofluorescence
background values were determined by averaging the fluorescence signals of 10 DAPI-stained nuclei in the CP per image (as CP
nuclei lacked YAP immunoreactivity, see Figure 1); these background values were then subtracted from the respective total YAP
and phospho-YAP immunofluorescence values obtained for each of the Sox2-positive nuclei per cryosection. To be able to relate
the resulting, background-corrected, nuclear total YAP and nuclear phospho-YAP immunofluorescence values to each other, the
mean immunofluorescence values for total YAP and for phospho-YAP from three representative areas of cytoplasm per image
were determined. The ratio of mean cytoplasmic total YAP immunofluorescene value / mean cytoplasmic phospho-YAP immuno-
fluorescene value was multiplied with the nuclear phospho-YAP immunofluorescence values to yield the adjusted immunofluores-
cence values for nuclear phospho-YAP. Then, for each nucleus, the adjusted immunofluorescence value for phospho-YAP was
subtracted from the immunofluorescence value for total YAP, to yield the value for dephosphorylated, i.e., active, YAP.
Protein phosphatase treatment
To determine the proportion of YAP in Sox2+ nuclei in the SVZ that was in dephosphorylated form and hence active (Figure S2C),
immunofluorescence was performed as follows. Cryosections (3 mm) of fixed mouse, ferret and human neocortex of the indicated
developmental stages (1-2 cryosections per embryo/fetus) were subjected to antigen retrieval followed by permeabilization as
described above. Cryosections were then treated with lambda protein phosphatase (New England Biolabs, P0753S) in a total reac-
tion volume of 100 ml per cryosection, which consisted of 10 ml of 10x Protein MetalloPhosphatase buffer (50 mM HEPES pH 7.5,
10 mM NaCl, 2 mM DTT, 0.01% Brij 35; New England Biolabs, B0761S), 10 ml of 10 mM MnCl2, and either 10 ml of 400 units/ml of
lambda protein phosphatase plus 70 ml of water (phosphatase treatment), or 80 ml of water (control treatment). To control for the
specificity of phospho-YAP primary antibody (Cell Signaling, 13008), we incubated lambda protein phosphatase treated mouse
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experiment showed absence of immunofluorescence signal in treated sections. For each neocortex sample per species, three
cryosections were subjected to phosphatase treatment for 2 h at 37C in a humidified chamber, and three other cryosections
were subjected to control treatment. Cryosections were then washed in 0.3% Triton X-100 in 1x Tris-HCl buffered saline containing
0.2% gelatine (washing/blocking buffer), and blocked for 30 min in the same buffer followed by overnight incubation at 4C with a
mixture of two primary rabbit monoclonal antibodies diluted in washing/blocking buffer, one to detect total YAP (Cell Signaling,
14074, 1:100) and the other to detect phospho-YAP (Cell Signaling, 13008, 1:100), and polyclonal goat Sox2 antibody (R&D Systems,
AF2018, 1:100), followed by incubation in washing/blocking buffer containing the respective appropriate secondary antibodies,
anti-rabbit Alexa Fluor 488 and anti-goat Alexa Fluor 555 (Molecular Probes), for 2 h at room temperature. After a series of washes
in 1x PBS, cryosections were mounted to glass slides using Mowiol. Protein phosphatase treatment of mouse E14.5 neocortex was
found to completely abolish the immunofluorescence signal obtained with the phospho-YAP antibody, indicating of complete
dephosphorylation of serine112.
For the quantification of the YAP immunoreactivity detected with the mixture of the total YAP plus phospho-YAP antibodies upon
control versus phosphatase treatment, one image per cryosection was taken and 30 randomly selected Sox2-positive nuclei in the
SVZ were scored per cryosection. For each neocortex sample per species, after determining the average value per cryosection, the
mean of these average values for the three control cryosections was set to 100%, and the mean of the average values for the three
phosphatase-treated cryosections was expressed relative to this. The reduction, upon protein phosphatase treatment, in the YAP
immunofluorescence signal obtained with the sum of the two antibodies (total YAP plus phospho-YAP) indicates the contribution
of phospho-YAP to this signal.
QUANTIFICATION AND STATISTICAL ANALYSIS
Determination of germinal zones, apical and basal mitoses
Germinal zones were determined according to the differences in the cytoarchitecture as revealed by DAPI staining of nuclei. The VZ
was defined as the zone of a pseudostratified epithelium where nuclei are elongated, densely packed and radially aligned. The SVZ
was defined as the zone of non-radially aligned, rounded and less densely packed nuclei. In ferret and human, iSVZ and oSVZ were
distinguished according to the density of nuclei, where the iSVZ comprises densely packed rounded nuclei and the oSVZ comprises
sparse nuclei. The IZ was defined as the zone located between SVZ and CP, which had sparser nuclei than the SVZ (or the oSVZ in
ferret and human). The CP was defined as the zone of densely packed rounded nuclei beneath the pial surface. Apical mitoses were
defined as pVIM- or PH3-positive mitoses occurring within the VZ, and basal mitoses were defined as pVIM- or PH3-positive mitoses
occurring within the SVZ (Figures S4F, S4G, 5B, 5D, 6C, 6E, and 6F). Delaminated GFP-positive cells were defined as GFP-positive
cells lacking ventricular contact (Figure 7).
Quantifications
All quantifications were performed on 1-mmoptical sections, with the exception of pVIM staining in Figures 6E and 6F where 5 optical
sections were analyzed (5-mm Z stack). Quantifications were performed using the Fiji (Schindelin et al., 2012) software with the cell
counter plugin and/or ‘‘measure’’ function.
For Figures 2D, 2G, 3D, 3H, 4F, 4G, S4D, S4C, and S4F, nuclei were quantified based on the expression of the respective marker
combined with RFP expression. The scored double-positive nuclei (RFP plus selected marker) were expressed as a percentage of
the total number of RFP-positive nuclei in the given germinal zone. Quantification was done on 200-mmwide images, oriented parallel
to the apical surface.
Quantifications of RFP-positive nuclei in each zone (Figure S5D) were expressed as a percentage of the number of RFP-positive
nuclei in the given zone over the total number RFP-positive nuclei in the cortical wall.
To determine if a nucleus is YAP-positive (Figure 1), we measured and averaged the YAP immunofluorescence intensity for
10 nuclei located in the CP as background. In the VZ or SVZ, we scored a nucleus as YAP-positive if the immunofluorescence
intensity was at least two times higher than the background immunofluorescence. For quantification of YAP immunoreactivity, we
acquired two-three images per embryo/fetus, and in each image (i.e., each cryosection) 30 randomly selected DAPI-positive
(Figure 1D), Sox2-positive (Figure 1E), Tbr2-negative or -positive (Figures 1I–1K) nuclei in the VZ (Figures 1I and 1J) or in the SVZ
(Figures 1D, 1E, and 1K) were scored. The values obtained were averaged for each embryo/fetus. Data are expressed as the
percentage of 30 scored cells.
Data were tabulated in Excel (Microsoft, Redmond, WA) and analyzed in Prism 5 (GraphPad) software. Statistical analyses were
performed using unpaired Student’s t test, Mann-Whitney U-test, and one-way ANOVA test.e6 Cell Reports 27, 1103–1118.e1–e6, April 23, 2019
